Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIKTORY-2: T-DXd and Afatinib in HER2-low Advanced Gastric Cancer
NCT06085755Phase 2Recruiting
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan, afatinib in gastric cancer (GC), gastroesophageal junction adenocarcinoma. Started Sep 2024; status: recruiting.
02
Drugs
trastuzumab deruxtecanafatinib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06085755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06085755.